55 filings
Page 2 of 3
8-K
7znqjy2ziqxboy75
7 Nov 22
Inhibrx Reports Third Quarter 2022 Financial Results
4:05pm
8-K
v6dg7rjn6dn rrr56kly
26 Oct 22
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:10pm
8-K
h58rf2pq xyb
4 Oct 22
Entry into a Material Definitive Agreement
8:02am
8-K
l8u6bj105ajzmaogagp
15 Aug 22
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
4:09pm
8-K
wyxsny03hj 4d9
10 Aug 22
Regulation FD Disclosure
4:06pm
8-K
emcujb1lqgow4yvlf5nn
8 Aug 22
Inhibrx Reports Second Quarter 2022 Financial Results
4:19pm
8-K
7jez250a
30 Jun 22
Regulation FD Disclosure
9:01am
8-K
v6ysiok
16 Jun 22
Entry into a Material Definitive Agreement
4:05pm
8-K
eurt6n87
25 May 22
Submission of Matters to a Vote of Security Holders
5:23pm
8-K
dr7gjmlotrllq2g29
16 May 22
Regulation FD Disclosure
9:03am
8-K
evgi068fij5qeia2lht7
9 May 22
Inhibrx Reports First Quarter 2022 Financial Results
4:10pm
8-K
9b61cfebt7g0
25 Apr 22
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101
9:04am
8-K
50gvsk0
5 Apr 22
Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting
4:32pm
8-K
w20x te5kf4yqbb
4 Apr 22
Regulation FD Disclosure
4:06pm
8-K
zqd94ea5305zj
3 Mar 22
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
9:22am
8-K
9yfq4t04
28 Feb 22
Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results
4:12pm
8-K
6qh h2b3aqxlgxs5u
22 Feb 22
Inhibrx Announces Amended Loan Agreement with Oxford
9:11am
8-K
t8z1fz6s
25 Jan 22
Departure of Directors or Certain Officers
12:00am
8-K
f5t4oyr0
4 Jan 22
Regulation FD Disclosure
4:41pm
8-K
ptrbu
1 Dec 21
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma
4:07pm